Loading...
In a previous randomized study conducted in adolescents with autism spectrum disorders (ASDs), nasal oxytocin was not associated with improvement in caregiver-reported social responsiveness (NEJM JW Psychiatry Aug 22 2014; [e-pub] and J Child Psychol Psychiatry 2014; 55:98). Reasoning that earlier intervention might be more effective, investigators conducted a randomized, double-blind, placebo-controlled, crossover study of intranasal oxytocin in 31 young children with ASD (age range, 3–8 years; 87% male). Participants received twice-daily oxytocin nasal spray (12 IU/dose) or placebo for 5 weeks, followed by a 4-week washout before crossover.
Compared with placebo, oxytocin was associated with significant improvement in the primary outcome o…